Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
화요일, 9월 01

Kyverna Therapeutics Inc

KYTXNASDAQ
Trade with Public
Trade with Public
$8.47
0.111.25%
가까이에: Aug 28, 5:00 PM EST
$8.29
-0.08-0.96%
프리마켓: 8:42 AM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Kyverna Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Kyverna Therapeutics (KYTX).

Price Target Range — 7 Quarters

Analyst Consensus — 6 Analysts

6Buy
Consensus RatingOverweight# Analysts6Avg. Consensus PT$22Upside to Avg. PT+161.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jun 3, 2026HC Wainwright & Co.Mitchell S. KapoorMaintainedBuy$25
May 15, 2026HC Wainwright & Co.Mitchell S. KapoorPT RaiseBuy$20→$25
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $25 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Kyverna Therapeutics (NASDAQ:KYTX) with a Buy and maintains $25 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Kyverna Therapeutics, Raises Price Target to $25

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Buy and raises the price target from $20 to $25.
Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $29

JP Morgan analyst Brian Cheng maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight and lowers the price target from $30 to $29.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Kyverna Therapeutics (NASDAQ:KYTX) with a Buy and maintains $20 price target.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $33

Wells Fargo analyst Derek Archila maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight and raises the price target from $31 to $33.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $25

Morgan Stanley analyst Michael Ulz maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight and raises the price target from $20 to $25.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved